ArticleScientific reports2025
Sustainable production of silver chloride nanoparticles from desert flora for biomedical applications with multifunctional biological activities.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biofabrication ofPharmaceutics · 2026Article
- Phytosynthesis of Ag@AgCl nanoparticles using two types of bionanotechnological protocols exhibiting unique antimicrobial, antioxidant, and anti-inflammatory properties.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, Euphorbia sanctae-catharinae leaf extract is used for the first time to biosynthesize silver chloride nanoparticles (AgCl-NPs) via a green synthesis approach. The formation and properties of the AgCl-NPs were confirmed using various characterization techniques: UV-Vis spectroscopy showed a characteristic absorption peak at 430 nm, indicating nanoparticle formation; X-ray diffraction (XRD) analysis revealed a crystallite size of approximately 24 nm; transmission electron microscopy (TEM) showed predominantly spherical nanoparticles with sizes ranging from 20 to 50 nm; and Fourier-transform infrared spectroscopy (FTIR) identified functional groups from the plant extract involved in nanoparticle stabilization. The MIC values were 62.5 µg/mL for (S. aureus, E. coli, E. faecalis, S. faecalis, E. aerogenes), 250 µg/mL for (S. epidermidis, K. pneumoniae, R. ornithinolytica), and 125 µg/mL for P. aeruginosa. The MBC values were 500 µg/mL for (R. ornithinolytica, S. faecalis, K. pneumoniae, S. epidermidis), and 250 µg/mL for (S. aureus, E. coli, E. faecalis), and 125 µg/mL for E. aerogenes. Tetracycline's synergistic actions increased antibacterial effectiveness by 21.4-47%. Furthermore, at a non-toxic dose (MNTC: 31.25 µg/mL), AgCl-NPs showed strong antiviral activity against HSV-1, preventing viral multiplication by 74%. These results demonstrate the potential of AgCl-NPs produced from Euphorbia sanctae-catharinae as a sustainable substitute for fighting viral infections and antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.